Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.30
- Piotroski Score 2.00
- Grade Buy
- Symbol (ARDX)
- Company Ardelyx, Inc.
- Price $5.72
- Changes Percentage (-2.89%)
- Change -$0.17
- Day Low $5.65
- Day High $5.90
- Year High $10.13
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $15.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.28
- Trailing P/E Ratio -23.04
- Forward P/E Ratio -23.04
- P/E Growth -23.04
- Net Income $-66,067,000
Income Statement
Quarterly
Annual
Latest News of ARDX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Ardelyx, Inc. released a bullish quarterly report, exceeding revenue forecasts by 33% and reducing losses. Analysts predict a 36% revenue increase in 2024, with per-share losses projected to rise. Des...
By Yahoo! Finance | 3 months ago -
When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
Ardelyx, Inc. is a biopharmaceutical company focusing on gastrointestinal and cardiorenal medicines. Analysts predict the company to break even in 2025, with a 61% annual growth rate. However, high de...
By Yahoo! Finance | 4 months ago
